10-Q: Canopy Growth Narrows Loss, Boosts Cash Flow Amidst Strategic Shifts

Canopy Growth Corporation reported a significantly reduced net loss and improved cash flow from operations in Q1 2026, driven by strategic cost reductions and increased cannabis sales, despite declining gross margins and ongoing legal challenges.

Summary

• Net revenue increased by 9% to $72.1 million in Q1 2026, up from $66.2 million in Q1 2025.
• Cannabis segment net revenue grew by 24% to $57.0 million, primarily due to strong Canadian adult-use and medical cannabis sales.
• Canadian adult-use cannabis net revenue surged by 43% to $27.0 million, driven by flower and infused pre-rolled joint offerings.
• Canadian medical cannabis net revenue increased by 13% to $21.2 million, attributed to more insured customers and larger order sizes.
• Net loss from continuing operations significantly decreased by 68% to $41.5 million in Q1 2026, compared to $129.2 million in Q1 2025.
• Basic and diluted loss per share from continuing operations improved to $0.22 from $1.63 year-over-year.
• Net cash used in operating activities improved substantially, decreasing to $10.3 million from $51.8 million in the prior year.
• Free cash flow outflow improved to $11.6 million from $55.7 million in Q1 2025.
• Total debt outstanding decreased to $295.3 million as of June 30, 2025, from $304.1 million as of March 31, 2025.
• The company successfully extended the maturity date of its Credit Facility to September 18, 2027, through a US$100 million optional prepayment.
• Substantial doubt about the company's ability to continue as a going concern was alleviated due to balance sheet actions and a recent equity raise.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company significantly reduced its net loss and improved cash flow from operations, indicating better financial management and operational efficiency, the decline in gross margins and increased Adjusted EBITDA loss are concerning. The ongoing legal challenges and the inherent risks of the cannabis industry, particularly federal illegality in the U.S., temper the positive financial improvements. The alleviation of going concern doubt is a strong positive, but continued reliance on capital raises suggests ongoing financial needs.

Positives

• Net loss from continuing operations significantly narrowed by 68% to $41.5 million.
• Cash used in operating activities improved substantially, reducing to $10.3 million from $51.8 million.
• Free cash flow outflow improved to $11.6 million from $55.7 million, indicating better cash management.
• Overall net revenue increased by 9%, driven by strong performance in the Cannabis segment.
• Canadian adult-use cannabis net revenue grew by 43%, highlighting successful product offerings.
• Canadian medical cannabis net revenue increased by 13%, supported by an expanded customer base and product assortment.
• Total debt outstanding decreased, reflecting ongoing deleveraging efforts.
• The maturity date of the Credit Facility was extended to September 18, 2027, providing more financial flexibility.
• The company's management concluded that substantial doubt about its ability to continue as a going concern has been alleviated.

Negatives

• Gross margin percentage declined significantly to 25% from 35% in the prior year, primarily due to new product launch costs, product/geographical mix shifts, and increased freight costs.
• Adjusted EBITDA loss increased by 50% to $7.9 million, compared to a $5.3 million loss in the prior year, primarily due to softer gross margins.
• Storz & Bickel segment revenue decreased by 25% to $15.2 million, impacted by strong prior-year sales and consumer economic uncertainty.
• Interest income decreased by $1.0 million due to lower cash and short-term investment balances.
• The company continues to experience recurring losses from operations, necessitating additional capital to fund operations.

Risks

• Uncertainty regarding the application of U.S. state and federal law to cannabis and hemp products, including potential regulatory actions by federal agencies.
• Risk of impairment losses, including goodwill write-offs, due to market conditions or operational changes.
• Ability to refinance debt on favorable terms and comply with debt covenants remains a challenge.
• The company's strategy to accelerate entry into the U.S. cannabis market through Canopy USA, LLC, involves complex regulatory and operational risks.
• The Trust's future ownership interest in Canopy USA is not fully quantifiable, and the Trust may exert significant influence.
• Risks associated with Acreage's ability to satisfy its debt obligations, despite recent financing.
• Volatility in general economic, market, industry, or business conditions, including inflation, interest rates, and trade policy, could impact customer spending, costs, and margins.
• Compliance with evolving regulatory landscapes in the United States and other emerging markets.
• Health concerns related to vaping and cannabis products could impact sales and regulatory scrutiny.
• Reliance on licenses issued by governmental authorities and contractual arrangements, with risks of non-renewal or revocation.
• Inherent uncertainty associated with financial projections and future revenue levels.
• Risks related to third-party manufacturing and transportation.
• Exposure to risks of an agricultural business, including wholesale price volatility and variable product quality.
• Potential for inventory write-downs due to market changes or product obsolescence.
• Risks related to stock exchange restrictions and compliance with listing requirements.
• Challenges in protecting and enforcing intellectual property rights.
• The exchangeable shares having different rights from common shares and potential lack of a trading market for them.
• Uncertainty regarding the finalization of consideration payable for the acquisition of remaining interests in Jetty.

Future Outlook

The company continues to evaluate strategies to increase its liquidity position, including pursuing additional cost-savings and seeking further financing from public and private markets through equity and/or debt securities. It has a shelf registration statement for up to US$500 million in securities and US$105.6 million remaining under its February 2025 ATM Program. Mandatory prepayments on the Credit Facility are scheduled through March 2026. The company aims to maintain compliance with financial covenants, with targets for Senior Leverage Ratio and Minimum Interest Coverage Ratio decreasing over time, and a minimum cash balance of $6.5 million.

Management Comments

• Management concludes that the substantial doubt about the company's ability to continue as a going concern has been alleviated due to completed balance sheet actions and additional capital raises.
• The year-over-year increase in Canadian adult-use cannabis net revenue is primarily attributable to growth in flower and infused pre-rolled joint offerings.
• The increase in Canadian medical cannabis net revenue is primarily attributable to an increase in the number of insured customers, increased order sizes, and a larger assortment of cannabis product choices.
• The decrease in Storz & Bickel revenue is primarily attributable to lapping strong sales in the prior year and consumer economic uncertainty.
• The decrease in gross margin percentage is primarily attributable to costs related to new product launches, as well as shifts in both product and geographical mix, and increases in freight costs.
• The decrease in general and administrative expense is primarily attributable to continued reductions in headcount and lower third-party costs, including insurance, professional fees, and IT costs.
• The increase in sales and marketing expense is primarily attributable to increased costs associated with customer acquisition, royalties, and other variable marketing costs, partially offset by headcount reductions.
• The decrease in share-based compensation is primarily attributable to higher estimated forfeitures due to departures of certain executives and lower expense due to reduced headcount, offset by new option and restricted share unit grants.

Industry Context

The company operates in the highly regulated and evolving global cannabis market, with core operations in Canada, Europe, and Australia, and a significant non-controlling interest in the U.S. cannabis sector through Canopy USA. The U.S. market remains federally illegal, posing unique challenges and opportunities. The decline in Storz & Bickel revenue reflects broader consumer economic uncertainty impacting discretionary spending on accessories. The company's strategic shift to deconsolidate U.S. assets via Canopy USA aims to navigate federal illegality while positioning for future U.S. market entry upon federal permissibility. The ongoing legal and regulatory scrutiny, particularly the SEC investigation related to BioSteel, highlights the inherent compliance risks in the industry.

Comparison to Industry Standards

• The company's gross margin of 25% is lower than some established cannabis operators who have achieved higher efficiencies and scale, such as Green Thumb Industries (often above 50%) or Curaleaf (typically in the 40-50% range), indicating continued pressure on profitability from new product launches and operational costs.
• The improvement in net cash used in operating activities to -$10.3 million is a positive step towards cash flow neutrality, a key metric for many cannabis companies, though still an outflow. Companies like Trulieve Cannabis Corp. have demonstrated consistent positive operating cash flow, setting a benchmark for operational efficiency.
• The increase in Adjusted EBITDA loss to -$7.9 million, despite revenue growth, suggests that cost-cutting measures have not fully offset the impact of lower gross margins and other operational inefficiencies, contrasting with peers who are achieving positive Adjusted EBITDA through disciplined cost management and market share gains.
• The company's debt reduction efforts and maturity extension are crucial for financial stability, aligning with industry trends where companies are seeking to de-leverage and optimize capital structures in a challenging financing environment. However, the continued reliance on ATM programs for liquidity indicates ongoing capital needs, similar to other growth-focused but unprofitable companies in the sector.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action (Dziedziejko v. Canopy Growth Corporation et al.) is pending in the Ontario Superior Court of Justice, alleging misrepresentations in disclosures and seeking unspecified damages.
• Two other putative class actions in Ontario were stayed in favor of the Dziedziejko action.
• A putative class action (Asmaro v. Canopy Growth Corporation et al.) is pending in the Supreme Court of British Columbia, alleging misrepresentations and seeking unspecified damages.
• The company is the subject of an ongoing SEC investigation related to the BioSteel Review, following a voluntary self-report regarding revenue recognition issues. The outcome and potential impact are uncertain, with possible remedial measures, sanctions, fines, or penalties.
• A counterclaim was commenced in a private arbitration on February 4, 2025, seeking $6,399,700 in general damages and $1,000,000 in aggravated damages for alleged breaches of a share purchase agreement.
• A putative class action (Baron v. Canopy Growth Corporation et al.) was commenced in the U.S. District Court for the Eastern District of New York on April 4, 2025, alleging violations of U.S. federal securities laws related to overstated cost reduction efficacy and gross margin health, seeking unspecified damages.

Related Party Transactions

• Canopy Growth holds non-voting and non-participating shares in Canopy USA, LLC, and an interest in Canopy USA LPs, which are classified as equity method investments.
• Canopy USA holds 100% of Wana, approximately 77% of Jetty, and 100% of Acreage.
• Canopy USA LPs hold TerrAscend common shares and warrants.
• The Elevate loan receivable from Canopy Elevate I, LLC, Canopy Elevate II, LLC, and Canopy Elevate III, LLC is considered a related party loan following the deconsolidation of Canopy USA.
• The Subordinated Promissory Note is between the Borrower and Canopy USA, subject to a subordination agreement with Agent.

Stakeholder Impact

• **Shareholders**: Potential for increased value due to reduced net loss and improved cash flow, but diluted by ongoing share issuances through ATM programs. Exposure to significant legal and regulatory risks could impact share price.
• **Employees**: Continued headcount reductions in general and administrative functions, but increased costs in sales and marketing, indicating a shift in resource allocation. Executive departures led to share-based compensation adjustments.
• **Customers**: Increased product choices and order sizes for Canadian medical cannabis customers. Decline in Storz & Bickel sales suggests potential impact from consumer economic uncertainty.
• **Creditors**: Debt reduction and maturity extension of the Credit Facility improve the company's ability to meet its obligations. However, mandatory prepayments and ongoing capital raises indicate continued financial management efforts.
• **Suppliers**: No specific direct impact mentioned, but general business conditions and cost-saving initiatives could influence relationships.

Next Steps

• Continue to evaluate strategies to increase liquidity, including cost-savings initiatives.
• Pursue additional financing from public and private markets through equity and/or debt securities.
• Make mandatory prepayments on the Credit Facility: US$10 million by December 31, 2025, and US$15 million by March 31, 2026.
• Perform the next annual goodwill impairment analysis on March 31, 2026, or earlier if circumstances change.
• Vigorously defend against ongoing class action lawsuits and the SEC investigation related to BioSteel.

Key Dates

Recommendation

While Canopy Growth has shown significant improvements in reducing its net loss and enhancing cash flow from operations, indicating better financial discipline and operational efficiency, several factors warrant a 'hold' recommendation. The company continues to operate at a loss, and the increase in Adjusted EBITDA loss, coupled with declining gross margins, suggests persistent profitability challenges. The ongoing legal proceedings and the SEC investigation introduce substantial uncertainty and potential financial liabilities. Furthermore, the complex structure of Canopy USA and the inherent regulatory risks of the U.S. cannabis market remain significant overhangs. Although liquidity has improved and debt is being managed, the continued reliance on equity raises for funding indicates that the company is not yet self-sustaining. For a seasoned investor, the current improvements are positive signals, but the unresolved risks and lack of consistent profitability suggest a cautious approach, advising to hold existing positions and monitor developments closely before making further investment decisions.

Keywords

Cannabis, Marijuana, SEC Filing, 10-Q, Quarterly Report, Financial Results, Canopy Growth, CGC, Cannabis Industry, Storz & Bickel, Vaporizers, Debt Management, Liquidity, Going Concern, Canopy USA, Acreage Holdings, Wana, Jetty, TerrAscend, Financial Performance, Gross Margin, Adjusted EBITDA, Legal Proceedings, Capital Raise